2-Tert-butyl-5-cyclopropylpyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Tert-butyl-5-cyclopropylpyridine
• 英文别名: 2-tert-butyl-5-cyclopropylpyridine
• 化学式: C₁₂H₁₇N
• 分子量: 175.27
• InChiKey: FYPGPVAMFLDCKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• AGENTS FOR TREATING PAIN AND USES THEREOF
  申请人：ABBVIE INC.

  公开号：US20140171423A1

  公开（公告）日：2014-06-19

  This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这项发明涉及：(a) 化合物及其盐，用于治疗疼痛等症状；(b) 用于制备这些化合物和盐的中间体；(c) 包括这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包括这些化合物、盐和组合物的试剂盒。
• [EN] INHIBITORS OF NO PRODUCTION<br/>[FR] INHIBITEURS DE LA PRODUCTION DE NO
  申请人：MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT

  公开号：WO2022043465A1

  公开（公告）日：2022-03-03

  The invention relates to compounds useful as inhibitors of NO production, especially inhibitors of the inducible NO synthase iNOS expressed by microglia and macrophages. The invention also relates to pharmaceutical compositions comprising these compounds and to therapeutic uses of these compounds, especially in the prophylaxis or treatment of conditions characterized by excess NO production, such as ischemic stroke and retinopathies.

  本发明涉及一种化合物，其可用作NO产生的抑制剂，特别是可抑制由微胶质细胞和巨噬细胞表达的诱导型NO合酶iNOS的抑制剂。本发明还涉及含有这些化合物的药物组合物，以及这些化合物的治疗用途，特别是在预防或治疗由过量NO产生所表征的疾病中，如缺血性卒中和视网膜病。
• PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS
  申请人：Helal Christopher John

  公开号：US20140080806A1

  公开（公告）日：2014-03-20

  The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors.

  本发明提供了公式(I)的化合物及其药学上可接受的盐，以及制备这些化合物所使用的中间体、含有这些化合物的组合物和将这些化合物用作哺乳动物中治疗中枢神经系统疾病、认知障碍、精神分裂症、痴呆和其他疾病的方法。本发明还提供了公式(Id)的化合物及其药学上可接受的盐作为CYP3A4选择性抑制剂。
• TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170305902A1

  公开（公告）日：2017-10-26

  The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , L, X 1 , X 2 , and X 3 , are as defined herein. The compounds of the invention, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising them, are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a person in need thereof for diseases or disorders in which the mGluR2-NAM receptor plays a causative role, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders.
• PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF
  申请人：Sina Diana

  公开号：US20200277268A1

  公开（公告）日：2020-09-03

  The present application relates to sulfonamide containing compounds of Formulae (I) and (II) and compositions containing said compounds effective in the treatment of cell proliferative disorders, in particular cancer, and various methods of use thereof.